What is Genialis, Inc?
Genialis, Inc. operates at the vanguard of precision medicine, specializing in the application of artificial intelligence to oncology. By utilizing its proprietary Genialis Supermodel and sophisticated multiomics data infrastructure, the company provides therapeutic intelligence that spans the entire drug development lifecycle. The firm addresses the persistent challenge of patient variability, enabling more accurate patient stratification and significantly enhancing the probability of clinical success for novel cancer therapies. By bridging the gap between complex biological data and actionable clinical insights, Genialis is effectively redefining how promising molecules are translated into life-saving treatments.
How much funding has Genialis, Inc raised?
Genialis, Inc has raised a total of $15.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$13M
Angel/Seed (2017): $2.3M with participation from First Star Ventures and Redalpine
Series A (2023): $13M led by Taiwania Capital, First Star Ventures, and Debiopharm
Key Investors in Genialis, Inc
First Star Ventures
First Star is an investment firm focused on supporting visionary, technical founders who are inventing the future through advanced technologies such as AI/ML, decentralization, edge computing, and techbio.
Debiopharm
Debiopharm Investment serves as the investment division of Debiopharm Group, focusing on safeguarding capital and generating consistent financial returns through strategic private equity and real estate initiatives.
Redalpine
Redalpine is a thesis-driven venture capital firm with expertise in software and science, providing hands-on support to highly technical companies aiming to disrupt their respective industries.
What's next for Genialis, Inc?
With the recent influx of capital, Genialis, Inc. is well-positioned to scale its computational platform and expand its footprint within the global biopharmaceutical market. The strategic focus will likely center on deepening the capabilities of its multiomics infrastructure and accelerating the deployment of its AI models in active clinical settings. As the company continues to refine its therapeutic intelligence, it is expected to forge deeper partnerships with pharmaceutical entities seeking to optimize their oncology pipelines. The firm's ability to demonstrate improved clinical outcomes will be the primary catalyst for its next phase of growth, potentially setting a new industry standard for data-driven drug development.
See full Genialis, Inc company page
